Cart
sales@molnova.com
R162
CAS No. 64302-87-0
R162( R162 | R 162 | R-162 )
Catalog No. M17560 CAS No. 64302-87-0
R162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 69 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 428 | In Stock |
|
| 100MG | 610 | In Stock |
|
| 500MG | 1242 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameR162
-
NoteResearch use only, not for human use.
-
Brief DescriptionR162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
-
DescriptionR162 is an inhibitor of GDH activity and represses glioma cell growth.
-
In Vitro——
-
In Vivo——
-
SynonymsR162 | R 162 | R-162
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptorglutamate dehydrogenase 1 (GDH1)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number64302-87-0
-
Formula Weight264.28
-
Molecular FormulaC17H12O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL; 378.39 mM
-
SMILESO=C(C1=C2C=CC=C1)C3=CC=C(CC=C)C(O)=C3C2=O
-
Chemical Name2-Allyl-1-hydroxy-anthraquinone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jin L, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015 Feb 9;27(2):257-70.
molnova catalog
related products
-
PAT-505 B
PAT-505 is an orally available, selective and potent inhibitor of autologous epidermal growth factor (IC50 2 nM in Hep3B cells, 9.7 nM in human blood, 62 nM in mouse plasma).
-
WAY-270360
WAY-270360 is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.
-
Vandetanib
Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability.
